abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and @entity6 and XXXX versus @entity7 and @entity6 and @entity2 in the treatment of advanced @entity4 ].

answer: @entity2


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and @entity6 and @entity2 versus @entity7 and @entity6 and XXXX in the treatment of advanced @entity4 ].

answer: @entity2


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and @entity6 and @entity2 versus @entity7 and @entity6 and @entity2 in the treatment of advanced XXXX ].

answer: @entity4


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and XXXX and @entity2 versus @entity7 and @entity6 and @entity2 in the treatment of advanced @entity4 ].

answer: @entity6


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and @entity6 and @entity2 versus @entity7 and XXXX and @entity2 in the treatment of advanced @entity4 ].

answer: @entity6


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing @entity3 and @entity6 and @entity2 versus XXXX and @entity6 and @entity2 in the treatment of advanced @entity4 ].

answer: @entity7


abstract: BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: Sixty six @entity0 with advanced @entity4 were randomized into two groups:MVP arm (32 @entity0 , @entity3 6-8 mg/m   d1, @entity6 2-3 mg/m   d1 and d8, @entity2 70-80 mg/m   d1) and TVP arm (34 @entity0 , @entity7 40-50 mg/m   d1, @entity6 and @entity2 were the same as arm MVP). Characteristics of the @entity0 were similar in two arms. All @entity0 received two to four cycles of chemotherapy. RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological @entity1 . Grade III+IV hematological @entity1 were significantly higher in the @entity0 of arm TVP than arm MVP, especially @entity5 (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS: MVP regimen has a lower response rate and longer survival time but less hematological @entity1 than TVP regimen. The results suggest MVP regimen is a safe and active regimen for advanced @entity4 .

title: [A prospective randomized trial comparing XXXX and @entity6 and @entity2 versus @entity7 and @entity6 and @entity2 in the treatment of advanced @entity4 ].

answer: @entity3


abstract: Excitatory @entity0 transporters (EAAT) transport @entity1 into cells to regulate @entity1 neurotransmission and to maintain nontoxic extracellular @entity1 levels for neurons. We showed previously that the commonly used volatile anesthetic @entity2 increases the transporting activity of @entity4 , the major neuronal EAAT. This effect requires a protein kinase C (PKC) a-mediated and S465-dependent @entity4 redistribution to the plasma membrane. Thus, we hypothesize that specific peptides can be designed to block this effect. We conjugated a 10- @entity0 synthetic peptide with a sequence identical to that of @entity4 around the S465 to a peptide that can facilitate permeation of the plasma membrane. This fusion peptide inhibited the @entity2 -increased @entity4 activity and redistribution to the plasma membrane in C6 cells and hippocampus. It did not affect the basal @entity4 activity. This peptide also attenuated @entity2 -induced increase of @entity3 in the immunoprecipitates produced by an anti- @entity4 antibody. A scrambled peptide that has the same @entity0 composition as the S465 sequence-specific peptide but has a random sequence did not change the effects of @entity2 on @entity4 . The S465 sequence-specific peptide, but not the scrambled peptide, is a good @entity3 substrate in in vitro assay. These peptides did not affect cell viability. These results, along with our previous findings, strongly suggest that @entity3 interacts with @entity4 to regulate its functions. The S465 sequence-specific peptide may interrupt this interaction and is an effective inhibitor for the regulation of @entity4 activity and trafficking by @entity3 and @entity2 .

title: Inhibition of @entity2 -induced increase of cell-surface redistribution and activity of XXXX transporter type 3 by serine 465 sequence-specific peptides.

answer: @entity1


abstract: Excitatory @entity0 transporters (EAAT) transport @entity1 into cells to regulate @entity1 neurotransmission and to maintain nontoxic extracellular @entity1 levels for neurons. We showed previously that the commonly used volatile anesthetic @entity2 increases the transporting activity of @entity4 , the major neuronal EAAT. This effect requires a protein kinase C (PKC) a-mediated and S465-dependent @entity4 redistribution to the plasma membrane. Thus, we hypothesize that specific peptides can be designed to block this effect. We conjugated a 10- @entity0 synthetic peptide with a sequence identical to that of @entity4 around the S465 to a peptide that can facilitate permeation of the plasma membrane. This fusion peptide inhibited the @entity2 -increased @entity4 activity and redistribution to the plasma membrane in C6 cells and hippocampus. It did not affect the basal @entity4 activity. This peptide also attenuated @entity2 -induced increase of @entity3 in the immunoprecipitates produced by an anti- @entity4 antibody. A scrambled peptide that has the same @entity0 composition as the S465 sequence-specific peptide but has a random sequence did not change the effects of @entity2 on @entity4 . The S465 sequence-specific peptide, but not the scrambled peptide, is a good @entity3 substrate in in vitro assay. These peptides did not affect cell viability. These results, along with our previous findings, strongly suggest that @entity3 interacts with @entity4 to regulate its functions. The S465 sequence-specific peptide may interrupt this interaction and is an effective inhibitor for the regulation of @entity4 activity and trafficking by @entity3 and @entity2 .

title: Inhibition of XXXX -induced increase of cell-surface redistribution and activity of @entity1 transporter type 3 by serine 465 sequence-specific peptides.

answer: @entity2


abstract: @entity6 provide the major hormonal support for endocrine-dependent @entity1 mammary @entity2 . In postmenopausal @entity1 , the extraglandular aromatization of the adrenal prehormone, @entity9 to @entity8 is the major pathway for @entity6 biosynthesis. @entity8 can then be converted into @entity4 or into an inactive conjugate, @entity13 . Recent data suggest that the @entity6 may also be synthesized in situ by @entity1 @entity0 , either from @entity9 via aromatase, or from @entity13 via the enzyme, @entity12 . Our enzyme kinetic studies support the predominance of the @entity12 pathway for in situ @entity6 biosynthesis. The ability of @entity13 to stimulate colony formation of the @entity11 -induced @entity3 mammary @entity2 in the clonogenic assay, suggests that this in situ pathway has biologic relevance. Aromatase inhibitors can be used to suppress the levels of circulating @entity8 , @entity13 , and @entity4 in postmenopausal @entity1 . @entity10 , the major inhibitor currently used clinically, acts in a competitive fashion and blocks @entity5 side chain cleavage and 11 beta-hydroxylase as well as aromatase. Clinical studies indicate that the combination of @entity10 plus replacement glucocorticoid causes @entity0 regression with the same frequency and for the same duration as surgical ablative therapies such as adrenalectomy or hypophysectomy. @entity10 also induces a similar rate of @entity2 regression as achieved with the antiestrogen, @entity7 . However, because @entity7 is associated with fewer side effects, this antiestrogen is to be preferred over use of @entity10 as first-line hormonal treatment for @entity1 with @entity0 . Several specific suicide inhibitors of @entity10 such as @entity14 are being developed and have proven effective in early clinical trials with @entity0 @entity1 . Further development of active aromatase inhibitors should allow precise control of @entity4 levels in @entity1 with @entity0 . This ability to perform an ' @entity6 clamp' may allow new strategies to be developed in which hormone depletion followed by repletion can produce a synchronization of @entity2 cell DNA synthesis. If achievable, such manipulations may allow potentiation of the effects of cytotoxic chemotherapy. This latter concept is currently being rigorously tested in basic and in clinical investigative studies.

title: Aromatase inhibitors for treatment of XXXX : current concepts and new perspectives.

answer: @entity0


abstract: In a period from 1982-2002 we noticed five dead among Croatian male physicians aged 34 to 67, during or after recreational physical exercise: swimming, soccer, tennis and jogging. Three of them who were autopsied, have been non-smokers and without previous symptoms. In all @entity4 was found. The left descending anterior artery was stenotic in one and occluded in two, with @entity3 in one. An @entity5 was found in none of them, and in two-left @entity1 15 and 18 mm. We could not find a recent medical record in those physicians including a clinical finding and other findings. Two physicians who were not been autopsied, had possible an @entity2 @entity3 . Both of them were smokers. In Croatia about 7% of the whole population are engaged in recreational physical exercise. In a period of twenty years (1982-2002) we noticed 43 sudden and unexpected deaths during or immediately after physical exercise: it reached 43/6,300,000 @entity6 in Croatia in twenty years or 2.15/315,000 yearly among @entity0 engaged in physical exercise. In Croatia there are 4,957 male physicians-specialists, and a rate of @entity7 during or immediately after physical exercise in this group reached 5/99,140 in 20 years or 1/19,828 every four years. A medical check up before recreational physical exercise is essential including a clinical examination, a serum concentration of risk factors and other risk factors, an electrocardiogram at rest, a stress test and echocardiography in clinical indication, as are medical controls over @entity0 taking exercise. This study shows that medical evaluation is important because of the underlying problems such as @entity6 during exercise. In non-trained @entity0 and in the elderly a physical exercise should be recommended of a gradually intensity, which could not exceed 6 METs.

title: XXXX due to recreational exercise in physicians.

answer: @entity6


abstract: The field of intravenous and intra-arterial thrombolysis for the treatment of acute @entity1 is rapidly advancing. Limitations of existing thrombolytic agents have prompted the development of new thrombolytic agents over the last decade. These new agents are broadly classified as third generation thrombolytics. Two of the several third generation thrombolytic agents have been investigated for the treatment of acute @entity1 and include tenecteplase (Genentech Inc) and reteplase (Roche Holding AG). By virtue of structural modifications, third generation thrombolytics have longer half-lives and greater penetration into the thrombus matrix. Tenecteplase has been evaluated in experimental models of @entity1 . These experimental studies have observed faster and more complete recanalization of occluded arteries compared with second-generation thrombolytics. The first prospective @entity0 clinical trial evaluated the safety and efficacy of intra-arterial reteplase in 16 @entity0 with @entity1 who were poor candidates for intravenous alteplase therapy. Near complete or complete recanalization was observed after treatment in 88% of the @entity0 . The development and use of third generation thrombolytics is expected to increase the rate of recanalization and clinical recovery in @entity0 with @entity1 . Clinical trials are required to determine the appropriate dose and @entity0 selection for these emerging pharmacological agents.

title: Third generation thrombolytics for the treatment of XXXX .

answer: @entity1


abstract: INTRODUCTION: In Austria, @entity1 , @entity6 as well as oral slow-release @entity3 are used for the treatment of @entity7 . This controlled examination marks the first time that oral slow-release @entity8 is applied for maintenance therapy in opioid dependent subjects. METHODS: In order to evaluate the effectiveness of this psychopharmacological medication, we examined @entity0 over a three-week period. Outcome measures were retention rate, additional consumption and the evaluation of opioid withdrawal 24 hours after the last oral medication. RESULTS: Sixty-seven @entity0 were included; sixty-four @entity0 completed the study, representing a retention rate of 94%. During the three-week period, a significant improvement in well-being and a significant reduction in @entity5 , @entity4 and @entity2 craving (p < 0.0001) was evaluated. Furthermore, there was a significant reduction of additional consumption of @entity2 in supervised urinalysis. Additional consumption of @entity4 remained unchanged. Laboratory results showed a significant reduction of CK over the course of investigation. DISCUSSION: The high retention rate of 94% implies a good acceptance and efficacy of the substance. The reduced CK is consistent with a reduction in intravenous application of illegal substances. However, randomized double-blind, double-dummy studies with oral slow-release @entity3 are needed in order to meet criteria for evidence based medicine.

title: [Slow-release XXXX for maintenance therapy of @entity7 ].

answer: @entity8


abstract: INTRODUCTION: In Austria, @entity1 , @entity6 as well as oral slow-release @entity3 are used for the treatment of @entity7 . This controlled examination marks the first time that oral slow-release @entity8 is applied for maintenance therapy in opioid dependent subjects. METHODS: In order to evaluate the effectiveness of this psychopharmacological medication, we examined @entity0 over a three-week period. Outcome measures were retention rate, additional consumption and the evaluation of opioid withdrawal 24 hours after the last oral medication. RESULTS: Sixty-seven @entity0 were included; sixty-four @entity0 completed the study, representing a retention rate of 94%. During the three-week period, a significant improvement in well-being and a significant reduction in @entity5 , @entity4 and @entity2 craving (p < 0.0001) was evaluated. Furthermore, there was a significant reduction of additional consumption of @entity2 in supervised urinalysis. Additional consumption of @entity4 remained unchanged. Laboratory results showed a significant reduction of CK over the course of investigation. DISCUSSION: The high retention rate of 94% implies a good acceptance and efficacy of the substance. The reduced CK is consistent with a reduction in intravenous application of illegal substances. However, randomized double-blind, double-dummy studies with oral slow-release @entity3 are needed in order to meet criteria for evidence based medicine.

title: [Slow-release @entity8 for maintenance therapy of XXXX ].

answer: @entity7


abstract: Parelaphostrongylosis has a rapid onset and is lethal in neonatal moose (Alces alces) when large numbers of third-stage Parelaphostrongylus tenuis larvae (L3) are given experimentally. Little is known, however, about the severity and prognosis of @entity0 acquired naturally by accidentally ingesting terrestrial gastropods which are rarely infected and have few larvae. To investigate the relationship between infecting dose, age of moose, and severity of disease, five @entity1 were given low doses of three to 10 L3 when five (n = 2) or 9.5 mo old (n = 3). Each of two animals initially given low doses were later challenged with a dose of 15 L3. As positive controls, two @entity1 were given doses of 15 and 30 L3, considered to be high. All five @entity1 given low doses showed abnormal locomotory signs at 20-28 days postinoculation (DPI) that progressively became more pronounced with hind @entity2 and @entity3 . However, after 77-130 DPI, signs diminished markedly in two of these animals and disappeared in another two. Challenge @entity0 of 15 L3 given 199 days after @entity0 had no noticeable effects although an immature worm, probably resulting from the challenge, was found in the spinal cord of one animal killed 51 days later. Two positive control animals given the high doses of 15 and 30 L3 showed moderate to severe, non-resolving, locomotory signs and had to be euthanized. Results demonstrate that single, low doses of three to 10 P. tenuis L3 cause moderate disease in moose @entity1 but over time, some worms die and animals can recover. A degree of protection may develop against @entity0 .

title: Low-dose meningeal worm (Parelaphostrongylus tenuis) XXXX in moose (Alces alces).

answer: @entity0


abstract: OBJECTIVE: Early and accurate risk prediction of walking limitations after @entity2 ( @entity2 ) is important for clinical and economic reasons. However, to our knowledge, no studies have systematically integrated multiple predictors into a single, clinically practical model. Our study aimed to develop a prediction model to estimate the risk of post- @entity2 walking limitations. METHODS: We performed a prospective cohort study of 1096 @entity0 who underwent elective, primary @entity2 between July 2013 and September 2014. Candidate predictors included @entity0 demographics, surgical factors, and pre- and early (1-mo) post- @entity2 functional measures. The outcome of interest was self-reported walking limitations at 6 months of post- @entity2 . We used multivariable proportional odds regression with bootstrap internal validation to develop the model. RESULTS: In all, 12% of @entity0 reported walking limitations (maximum walk time  <= 15 min) at 6 months postsurgery. The main predictors of increasing levels of walking limitations were preoperative walking limitations (overall p < 0.001), higher levels of body mass index [interquartile range (IQR)-OR 1.3, 95% CI 1.2-1.5], lower values of 1-month post- @entity2 gait speed (IQR-OR 1.9, 95% CI 1.3-2.6), the presence of contralateral knee @entity1 (OR 1.9, 95% CI 1.2-3.0), and the use of a quadstick preoperatively (OR 3.5, 95% CI 1.7-7.3). The prediction model had an optimism-corrected concordance index of 0.71. CONCLUSION: A small but sizable proportion of @entity0 with @entity2 had persistent mobility limitations. Our prediction model may help to risk-stratify @entity0 , and external validation is required before the model can be used in clinical practice.

title: Development of a Prediction Model to Estimate the Risk of Walking Limitations in XXXX with Total Knee Arthroplasty.

answer: @entity0


abstract: 108 @entity0 who received @entity4 or @entity6 could be evaluated for nephrotoxicity in a prospective randomized trial. Both groups had similar illnesses, and causative agents, concurrent drug administration, ages, sex ratios, initial serum @entity2 and @entity5 levels and total dose and duration of therapy. Using urinary concentration of @entity3 ( @entity3 ) as a marker, nephrotoxicity was detected in 13 (22.4%) of 58 @entity0 given @entity4 and 13 (26%) of 50 given @entity6 (n.s.). Using serum @entity2 as a marker, nephrotoxicity was detected in 3 (5.2%) of 58 @entity0 given @entity4 and in 7 (14%) of 50 given @entity6 (n.s.). The whole group of 108 @entity0 was used to compare the usefulness of serum @entity2 levels versus urinary concentration of @entity3 . An elevation of serum @entity2 was detected in 10 of 108 @entity0 (9.3%). In 5 of these 10 @entity0 the @entity3 remained normal, suggesting a functional @entity1 . In 21 of the 108 @entity0 (19.4%) the @entity3 increased while the serum @entity2 remained normal, suggesting an @entity5 nephrotoxicity which would have remained undetected if only serum @entity2 had been measured. In the remaining @entity0 (77 of the 108; 71.3%) serum @entity2 and urinary concentration of @entity3 both remained normal throughout the treatment. In conclusion no statistically significant differences were found between @entity4 and @entity6 nephrotoxicity. Urinary @entity3 is more sensitive than serum @entity2 and furthermore it allows one to differentiate @entity5 nephrotoxicity from functional @entity1 .

title: @entity4 and @entity6 nephrotoxicity. Value of serum XXXX versus urinary concentration of @entity3 .

answer: @entity2


abstract: 108 @entity0 who received @entity4 or @entity6 could be evaluated for nephrotoxicity in a prospective randomized trial. Both groups had similar illnesses, and causative agents, concurrent drug administration, ages, sex ratios, initial serum @entity2 and @entity5 levels and total dose and duration of therapy. Using urinary concentration of @entity3 ( @entity3 ) as a marker, nephrotoxicity was detected in 13 (22.4%) of 58 @entity0 given @entity4 and 13 (26%) of 50 given @entity6 (n.s.). Using serum @entity2 as a marker, nephrotoxicity was detected in 3 (5.2%) of 58 @entity0 given @entity4 and in 7 (14%) of 50 given @entity6 (n.s.). The whole group of 108 @entity0 was used to compare the usefulness of serum @entity2 levels versus urinary concentration of @entity3 . An elevation of serum @entity2 was detected in 10 of 108 @entity0 (9.3%). In 5 of these 10 @entity0 the @entity3 remained normal, suggesting a functional @entity1 . In 21 of the 108 @entity0 (19.4%) the @entity3 increased while the serum @entity2 remained normal, suggesting an @entity5 nephrotoxicity which would have remained undetected if only serum @entity2 had been measured. In the remaining @entity0 (77 of the 108; 71.3%) serum @entity2 and urinary concentration of @entity3 both remained normal throughout the treatment. In conclusion no statistically significant differences were found between @entity4 and @entity6 nephrotoxicity. Urinary @entity3 is more sensitive than serum @entity2 and furthermore it allows one to differentiate @entity5 nephrotoxicity from functional @entity1 .

title: @entity4 and @entity6 nephrotoxicity. Value of serum @entity2 versus urinary concentration of XXXX .

answer: @entity3


abstract: 108 @entity0 who received @entity4 or @entity6 could be evaluated for nephrotoxicity in a prospective randomized trial. Both groups had similar illnesses, and causative agents, concurrent drug administration, ages, sex ratios, initial serum @entity2 and @entity5 levels and total dose and duration of therapy. Using urinary concentration of @entity3 ( @entity3 ) as a marker, nephrotoxicity was detected in 13 (22.4%) of 58 @entity0 given @entity4 and 13 (26%) of 50 given @entity6 (n.s.). Using serum @entity2 as a marker, nephrotoxicity was detected in 3 (5.2%) of 58 @entity0 given @entity4 and in 7 (14%) of 50 given @entity6 (n.s.). The whole group of 108 @entity0 was used to compare the usefulness of serum @entity2 levels versus urinary concentration of @entity3 . An elevation of serum @entity2 was detected in 10 of 108 @entity0 (9.3%). In 5 of these 10 @entity0 the @entity3 remained normal, suggesting a functional @entity1 . In 21 of the 108 @entity0 (19.4%) the @entity3 increased while the serum @entity2 remained normal, suggesting an @entity5 nephrotoxicity which would have remained undetected if only serum @entity2 had been measured. In the remaining @entity0 (77 of the 108; 71.3%) serum @entity2 and urinary concentration of @entity3 both remained normal throughout the treatment. In conclusion no statistically significant differences were found between @entity4 and @entity6 nephrotoxicity. Urinary @entity3 is more sensitive than serum @entity2 and furthermore it allows one to differentiate @entity5 nephrotoxicity from functional @entity1 .

title: @entity4 and XXXX nephrotoxicity. Value of serum @entity2 versus urinary concentration of @entity3 .

answer: @entity6


abstract: 108 @entity0 who received @entity4 or @entity6 could be evaluated for nephrotoxicity in a prospective randomized trial. Both groups had similar illnesses, and causative agents, concurrent drug administration, ages, sex ratios, initial serum @entity2 and @entity5 levels and total dose and duration of therapy. Using urinary concentration of @entity3 ( @entity3 ) as a marker, nephrotoxicity was detected in 13 (22.4%) of 58 @entity0 given @entity4 and 13 (26%) of 50 given @entity6 (n.s.). Using serum @entity2 as a marker, nephrotoxicity was detected in 3 (5.2%) of 58 @entity0 given @entity4 and in 7 (14%) of 50 given @entity6 (n.s.). The whole group of 108 @entity0 was used to compare the usefulness of serum @entity2 levels versus urinary concentration of @entity3 . An elevation of serum @entity2 was detected in 10 of 108 @entity0 (9.3%). In 5 of these 10 @entity0 the @entity3 remained normal, suggesting a functional @entity1 . In 21 of the 108 @entity0 (19.4%) the @entity3 increased while the serum @entity2 remained normal, suggesting an @entity5 nephrotoxicity which would have remained undetected if only serum @entity2 had been measured. In the remaining @entity0 (77 of the 108; 71.3%) serum @entity2 and urinary concentration of @entity3 both remained normal throughout the treatment. In conclusion no statistically significant differences were found between @entity4 and @entity6 nephrotoxicity. Urinary @entity3 is more sensitive than serum @entity2 and furthermore it allows one to differentiate @entity5 nephrotoxicity from functional @entity1 .

title: XXXX and @entity6 nephrotoxicity. Value of serum @entity2 versus urinary concentration of @entity3 .

answer: @entity4


abstract: UNASSIGNED: @entity4 is a rare but lethal @entity1 . The optimal treatment for advanced @entity4 is not yet established. This report is the first known of stereotactic ablative radiotherapy (sabr) with CyberKnife (Accuray, Sunnyvale, CA, U.S.A.) as definitive therapy for @entity4 . The @entity0 , a 70-year-old @entity0 with @entity4 , invasion into neighboring organs, and pleural metastases-underwent CyberKnife sabr at 40 Gy in 5 fractions for two lesions, one in the thymus and one in the right paraspinal pleura. After 61 months of observation, a partial response was observed in the irradiated fields. However, disease progression in the non-irradiated pleura was noted. The @entity0 underwent salvage CyberKnife sabr for the four initially nonirradiated @entity3 . Computed tomography images obtained 10 months after the salvage therapy revealed a partial response. The @entity0 is living, with progression-free irradiated lesions and no radiation-related @entity2 . CyberKnife sabr is feasible for @entity0 who are unable to undergo either surgery or conventionally fractionated radiation therapy.

title: Stereotactic ablative radiotherapy with CyberKnife for advanced XXXX : a case report.

answer: @entity4


abstract: UNASSIGNED: @entity1 smoke air pollution (TSAP) measurement may persuade parents to adopt smoke-free homes and thereby reduce harm to @entity0 from @entity1 smoke in the home. In a pilot study involving 29 smoking families, a Sidepak was used to continuously monitor home PM2.5 during an 8-h period, Sidepak and/or Dylos monitors provided real-time feedback, and passive @entity2 monitors were used to measure home air @entity2 for one week. Feedback was provided to @entity0 in the context of motivational interviews. Home PM2.5 levels recorded by continuous monitoring were not well-accepted by @entity0 because of the noise level. Also, graphs from continuous monitoring showed unexplained peaks, often associated with sources unrelated to indoor smoking, such as cooking, construction, or outdoor sources. This hampered delivery of a persuasive message about the relationship between home smoking and TSAP. By contrast, immediate real-time PM2.5 feedback (with Sidepak or Dylos monitor) was feasible and provided unambiguous information; the Dylos had the additional advantages of being more economical and quieter. Air @entity2 sampling was complicated by the time-lag for feedback and questions regarding shelf-life. Improvement in the science of TSAP measurement in the home environment is needed to encourage and help maintain smoke-free homes and protect vulnerable @entity0 . Recent advances in the use of mobile devices for real-time feedback are promising and warrant further development, as do accurate methods for real-time air @entity2 air monitoring.

title: Feasibility of Measuring XXXX Smoke Air Pollution in Homes: Report from a Pilot Study.

answer: @entity1


abstract: UNASSIGNED: The liver has a remarkable regeneration capacity, and, after surgical removal of its mass, the remaining tissue undergoes rapid regeneration through compensatory growth of its constituent cells. Although hepatocytes synchronously proliferate under the control of various signaling molecules from neighboring cells, there have been few detailed analyses on how biliary cells regenerate for their cell population after liver resection. The present study was undertaken to clarify how biliary cells regenerate after partial hepatectomy of @entity0 through extensive analyses of their cell cycle progression and gene expression using immunohistochemical and RT-PCR techniques. When expression of @entity2 , @entity3 antigen, topoisomerase @entity6 and phosphorylated histone H3, which are cell cycle markers, was immunohistochemically examined during liver regeneration, hepatocytes had a peak of the S phase and M phase at 48-72 h after resection. By contrast, biliary epithelial cells had much lower proliferative activity than that of hepatocytes, and their peak of the S phase was delayed. Mitotic figures were rarely detectable in biliary cells. RT-PCR analyses of gene expression of biliary markers such as @entity1 (osteopontin), @entity7 and @entity8 demonstrated that they were upregulated during liver regeneration. Periportal hepatocytes expressed some of biliary markers, including @entity1 mRNA and protein. Some periportal hepatocytes had downregulated expression of @entity4 and @entity5 . Gene expression of Notch signaling molecules responsible for cell fate decision of hepatoblasts to biliary cells during development was upregulated during liver regeneration. Notch signaling may be involved in biliary regeneration.

title: Immunohistochemical analyses of cell cycle progression and gene expression of biliary epithelial cells during liver regeneration after partial hepatectomy of the XXXX .

answer: @entity0


abstract: Exposure of male and female @entity3 to elevated ambient temperatures can result in reduced reproductive efficiency. When boars and gilts are exposed to heat stress, respiratory rates increase to enhance evaporative cooling because minimal sweating occurs. During early pregnancy, gilts are especially susceptible to heat stress. Decreased conception rates and reduced litter size occur when gilts are exposed to elevated ambient temperature during Days 0 to 16 after mating. Concentrations of @entity2 in peripheral plasma were reduced during Days 13-19 after mating and luteal function was extended to Day 25 in heat-stressed gilts that did not conceive. Increased concentrations of @entity0 during Day 10 to 12 of heat stress may interfere with normal maternal recognition of pregnancy. Heat stress reduced the amount of embryonic tissue present at Day 16 of pregnancy but the protein synthetic activity of the tissue was not altered. Thus some embryos may be lost and a reduction in litter size may occur. The production of @entity4 by the conceptus and uterus is not altered on Day 16, after exposure to heat stress for the previous 8 days. These studies suggest that heat stress during early pregnancy can alter the reproductive endocrine system, especially the control of luteal function. In addition, heat stress may have a direct effect on embryo or conceptus development. Exposure of boars to elevated ambient temperatures causes reductions in semen quality, sperm output and fertility. About 5 weeks are required for boars to recover from the detrimental effects of heat stress and to produce semen with potential for maximal fertility. Increased temperature has an inhibitory effect on spermatid maturation and on testicular @entity1 biosynthesis. Improvements in reproductive performance can be achieved by increasing evaporative cooling of boars.

title: Influence of environmental temperature on prolificacy of XXXX .

answer: @entity3


abstract: BACKGROUND: Nearly 30% of @entity0 with @entity1 continue to have @entity2 in spite of using several antiepileptic drug (AED) regimens. Such @entity0 are regarded as having refractory, or uncontrolled, @entity1 . No definition of uncontrolled, or medically refractory, @entity1 has been universally accepted, but for the purposes of this review, we will consider @entity2 as drug resistant if they have failed to respond to a minimum of two AEDs. It is believed that early surgical intervention may prevent @entity2 at a younger age, which, in turn, may improve the intellectual and social status of @entity0 . Many types of surgery are available for treatment of @entity1 ; one such procedure is known as subpial transection. OBJECTIVES: To determine the benefits and adverse effects of subpial transection for partial-onset @entity2 and generalised @entity2 in @entity0 and adults. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register (29 June 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; May 2015, Issue 5) and MEDLINE (1946 to 29 June 2015). We imposed no language restrictions. SELECTION CRITERIA: We considered all randomised and quasi-randomised parallel-group studies, whether blinded or non-blinded. DATA COLLECTION AND ANALYSIS: Two review authors (BK and SR) independently screened trials identified by the search. The same two review authors planned to independently assess the methodological quality of studies. When studies were identified for inclusion, one review author would have extracted the data, and the other would have verified the data. MAIN RESULTS: We found no relevant studies. AUTHORS' CONCLUSIONS: We found no evidence to support or refute use of subpial transection surgery for @entity0 with medically @entity1 . Well-designed randomised controlled trials are needed to guide clinical practice.

title: Subpial transection surgery for XXXX .

answer: @entity1


abstract: Ninety-four per cent of 169 @entity0 with @entity8 developed @entity3 (haematocrit less than 35 per cent) and 30 per cent required blood transfusion to maintain the haematocrit at more than 21 per cent. @entity3 was at its worst on admission in 58 @entity0 (34 per cent); in the rest the haematocrit fell further, reaching its nadir one to 17 days later (mean 2.3 days). The mean lowest haematocrit was 24.3 +/- 7.2 per cent (+/- 1 SD) and the mean maximum fall was 7.9 +/- 5.6 per cent. @entity3 was more severe in @entity0 with @entity6 , @entity7 , schizontaemia and in pregnancy. The lowest haematocrit correlated with admission parasitaemia (r = -0.33, p less than 0.001), total serum @entity4 (r = -0.25, p less than 0.01) and serum @entity5 (r = -0.22, p less than 0.01). In 23 @entity0 with uncomplicated @entity9 the mean serum @entity1 on admission was 53 micrograms/dl (range 16-157) and the mean serum ferritin 1773 ng/ml (range 170-10 000). There was a significant (p less than 0.001) rise in serum @entity1 96 h after starting antimalarial treatment; the serum ferritin declined slowly over several weeks. Stainable @entity1 was present in all marrows examined and in eight @entity0 the characteristic pattern of the @entity3 of @entity2 was seen. Seventy-three per cent of @entity0 had @entity10 which was moderate to gross in 36 per cent. @entity10 and erythrophagocytosis were often present on admission but sometimes appeared after the parasitaemia had cleared and persisted for at least three weeks into convalescence. These disturbances in @entity1 metabolism and haemopoiesis are not completely explicable by red blood cell parasitisation. They may contribute more to the @entity3 than has previously been recognised.

title: The importance of @entity3 in cerebral and uncomplicated XXXX : role of complications, @entity10 and @entity1 sequestration.

answer: @entity9


abstract: Ninety-four per cent of 169 @entity0 with @entity8 developed @entity3 (haematocrit less than 35 per cent) and 30 per cent required blood transfusion to maintain the haematocrit at more than 21 per cent. @entity3 was at its worst on admission in 58 @entity0 (34 per cent); in the rest the haematocrit fell further, reaching its nadir one to 17 days later (mean 2.3 days). The mean lowest haematocrit was 24.3 +/- 7.2 per cent (+/- 1 SD) and the mean maximum fall was 7.9 +/- 5.6 per cent. @entity3 was more severe in @entity0 with @entity6 , @entity7 , schizontaemia and in pregnancy. The lowest haematocrit correlated with admission parasitaemia (r = -0.33, p less than 0.001), total serum @entity4 (r = -0.25, p less than 0.01) and serum @entity5 (r = -0.22, p less than 0.01). In 23 @entity0 with uncomplicated @entity9 the mean serum @entity1 on admission was 53 micrograms/dl (range 16-157) and the mean serum ferritin 1773 ng/ml (range 170-10 000). There was a significant (p less than 0.001) rise in serum @entity1 96 h after starting antimalarial treatment; the serum ferritin declined slowly over several weeks. Stainable @entity1 was present in all marrows examined and in eight @entity0 the characteristic pattern of the @entity3 of @entity2 was seen. Seventy-three per cent of @entity0 had @entity10 which was moderate to gross in 36 per cent. @entity10 and erythrophagocytosis were often present on admission but sometimes appeared after the parasitaemia had cleared and persisted for at least three weeks into convalescence. These disturbances in @entity1 metabolism and haemopoiesis are not completely explicable by red blood cell parasitisation. They may contribute more to the @entity3 than has previously been recognised.

title: The importance of @entity3 in cerebral and uncomplicated @entity9 : role of complications, XXXX and @entity1 sequestration.

answer: @entity10


abstract: Ninety-four per cent of 169 @entity0 with @entity8 developed @entity3 (haematocrit less than 35 per cent) and 30 per cent required blood transfusion to maintain the haematocrit at more than 21 per cent. @entity3 was at its worst on admission in 58 @entity0 (34 per cent); in the rest the haematocrit fell further, reaching its nadir one to 17 days later (mean 2.3 days). The mean lowest haematocrit was 24.3 +/- 7.2 per cent (+/- 1 SD) and the mean maximum fall was 7.9 +/- 5.6 per cent. @entity3 was more severe in @entity0 with @entity6 , @entity7 , schizontaemia and in pregnancy. The lowest haematocrit correlated with admission parasitaemia (r = -0.33, p less than 0.001), total serum @entity4 (r = -0.25, p less than 0.01) and serum @entity5 (r = -0.22, p less than 0.01). In 23 @entity0 with uncomplicated @entity9 the mean serum @entity1 on admission was 53 micrograms/dl (range 16-157) and the mean serum ferritin 1773 ng/ml (range 170-10 000). There was a significant (p less than 0.001) rise in serum @entity1 96 h after starting antimalarial treatment; the serum ferritin declined slowly over several weeks. Stainable @entity1 was present in all marrows examined and in eight @entity0 the characteristic pattern of the @entity3 of @entity2 was seen. Seventy-three per cent of @entity0 had @entity10 which was moderate to gross in 36 per cent. @entity10 and erythrophagocytosis were often present on admission but sometimes appeared after the parasitaemia had cleared and persisted for at least three weeks into convalescence. These disturbances in @entity1 metabolism and haemopoiesis are not completely explicable by red blood cell parasitisation. They may contribute more to the @entity3 than has previously been recognised.

title: The importance of XXXX in cerebral and uncomplicated @entity9 : role of complications, @entity10 and @entity1 sequestration.

answer: @entity3


abstract: Ninety-four per cent of 169 @entity0 with @entity8 developed @entity3 (haematocrit less than 35 per cent) and 30 per cent required blood transfusion to maintain the haematocrit at more than 21 per cent. @entity3 was at its worst on admission in 58 @entity0 (34 per cent); in the rest the haematocrit fell further, reaching its nadir one to 17 days later (mean 2.3 days). The mean lowest haematocrit was 24.3 +/- 7.2 per cent (+/- 1 SD) and the mean maximum fall was 7.9 +/- 5.6 per cent. @entity3 was more severe in @entity0 with @entity6 , @entity7 , schizontaemia and in pregnancy. The lowest haematocrit correlated with admission parasitaemia (r = -0.33, p less than 0.001), total serum @entity4 (r = -0.25, p less than 0.01) and serum @entity5 (r = -0.22, p less than 0.01). In 23 @entity0 with uncomplicated @entity9 the mean serum @entity1 on admission was 53 micrograms/dl (range 16-157) and the mean serum ferritin 1773 ng/ml (range 170-10 000). There was a significant (p less than 0.001) rise in serum @entity1 96 h after starting antimalarial treatment; the serum ferritin declined slowly over several weeks. Stainable @entity1 was present in all marrows examined and in eight @entity0 the characteristic pattern of the @entity3 of @entity2 was seen. Seventy-three per cent of @entity0 had @entity10 which was moderate to gross in 36 per cent. @entity10 and erythrophagocytosis were often present on admission but sometimes appeared after the parasitaemia had cleared and persisted for at least three weeks into convalescence. These disturbances in @entity1 metabolism and haemopoiesis are not completely explicable by red blood cell parasitisation. They may contribute more to the @entity3 than has previously been recognised.

title: The importance of @entity3 in cerebral and uncomplicated @entity9 : role of complications, @entity10 and XXXX sequestration.

answer: @entity1


abstract: AIM: To compare the short term outcome of @entity4 ( @entity4 ) with that of laparoscopic colorectal resection (LC) for the treatment of early @entity2 that are not amenable to conventional endoscopic removal. METHODS: This was a retrospective cohort study. The clinical data of all consecutive @entity0 who underwent @entity4 for endoscopically assessed benign lesions that were larger than 2 cm in diameter from 2009 to 2013 were collected. These @entity0 were compared with a cohort of controls who underwent LC from 2005 to 2013. Lesions that were proven to be malignant by initial endoscopic biopsies were excluded. Mid and lower rectal lesions were not included because total mesorectal excision, which bears a more complicated postoperative course, is not indicated for lesions without histological proof of @entity1 . Both @entity4 and LC were performed by the same surgical unit with a standardized technique. The @entity0 were managed according to a standard protocol, and they were closely monitored for complications after the procedures. All hospital records were reviewed, and the following data were compared between the @entity4 and LC groups: @entity0 demographics, size and location of the lesions, procedure time, short-term clinical outcomes and pathology results. RESULTS: From 2005 to 2013, 65 @entity0 who underwent @entity4 and 55 @entity0 who underwent LC were included in this study. The two groups were similar in terms of sex (P = 0.41) and American Society of Anesthesiologist class (P = 0.58), although @entity0 in the @entity4 group were slightly older (68.6    9.4 vs 64.6    9.9, P = 0.03). @entity4 could be accomplished with a shorter procedure time (113    66 min vs 153    43 min, P < 0.01) for lesions of comparable size (3.0    1.2 cm vs 3.4    1.4 cm, P = 0.22) and location (colon/rectum: 59/6 vs colon/rectum: 52/3, P = 0.43). @entity4 appeared to be associated with a lower short-term complication rate, but the difference did not reach statistical significance (10.8% vs 23.6%, P = 0.06). In the LC arm, a total of 22 complications occurred in 13 @entity0 . A total of 7 complications occurred in the @entity4 arm, including 5 perforations and 2 episodes of @entity3 . All perforations were observed during the procedure and were successfully managed by endoscopic clipping without emergency surgical intervention. @entity0 in the @entity4 arm had a faster recovery than @entity0 in the LC arm, which included shorter time to resume normal diet (2 d vs 4 d, P = 0.01) and a shorter hospital stay (3 d vs 6 d, P < 0.01). CONCLUSION: @entity4 showed better short-term clinical outcomes in this study. Further prospective randomized studies will be required to evaluate the efficacy and superiority of colorectal @entity4 over LC.

title: Endoscopic submucosal dissection vs laparoscopic colorectal resection for early XXXX .

answer: @entity2


abstract: BACKGROUND: In @entity5 , platelets demonstrate increased reactivity and promote the development of @entity1 . OBJECTIVE: This study was carried out to investigate the contribution of the @entity4 receptor @entity12 -mediated pathway to @entity6 due to @entity5 . METHODS: @entity7 -deficient @entity0 and C57Bl/6 wild-type @entity0 were fed on normal chow and high-fat (Western or Paigen) diets for 8 weeks to generate differently elevated @entity2 levels. @entity12 receptor-induced functional responses via G(i) signaling were studied ex vivo when washed @entity0 platelets were activated by 2MeSADP and @entity11 agonist AYPGKF in the presence and absence of @entity9 . Platelet aggregation and secretion, a(IIb)b(3) receptor activation and the phosphorylation of @entity10 ( @entity10 ) and Akt were analyzed. RESULTS: Plasma @entity2 levels ranged from 69    10 to 1011    185 mg dL(-1) depending on diet in @entity0 with different genotypes. Agonist-dependent aggregation, dense and a-granule secretion and JON/A binding were gradually and significantly (P < 0.05) augmented at low agonist concentration in correlation with the increasing plasma @entity2 levels, even if elevated @entity8 generation was blocked. These functional responses were induced via increased levels of G(i) -mediated @entity10 and Akt phosphorylation in @entity3 @entity0 vs. normocholesterolemic animals. In addition, blocking of the @entity12 receptor by @entity13 (Cangrelor) resulted in strongly reduced @entity6 in @entity0 with elevated @entity2 levels compared with normocholesterolemic controls. CONCLUSIONS: These data revealed that the @entity12 receptor pathway was substantially involved in @entity6 associated with mild and severe @entity5 .

title: Contribution of the XXXX receptor-mediated pathway to @entity6 in @entity5 .

answer: @entity12


abstract: BACKGROUND: In @entity5 , platelets demonstrate increased reactivity and promote the development of @entity1 . OBJECTIVE: This study was carried out to investigate the contribution of the @entity4 receptor @entity12 -mediated pathway to @entity6 due to @entity5 . METHODS: @entity7 -deficient @entity0 and C57Bl/6 wild-type @entity0 were fed on normal chow and high-fat (Western or Paigen) diets for 8 weeks to generate differently elevated @entity2 levels. @entity12 receptor-induced functional responses via G(i) signaling were studied ex vivo when washed @entity0 platelets were activated by 2MeSADP and @entity11 agonist AYPGKF in the presence and absence of @entity9 . Platelet aggregation and secretion, a(IIb)b(3) receptor activation and the phosphorylation of @entity10 ( @entity10 ) and Akt were analyzed. RESULTS: Plasma @entity2 levels ranged from 69    10 to 1011    185 mg dL(-1) depending on diet in @entity0 with different genotypes. Agonist-dependent aggregation, dense and a-granule secretion and JON/A binding were gradually and significantly (P < 0.05) augmented at low agonist concentration in correlation with the increasing plasma @entity2 levels, even if elevated @entity8 generation was blocked. These functional responses were induced via increased levels of G(i) -mediated @entity10 and Akt phosphorylation in @entity3 @entity0 vs. normocholesterolemic animals. In addition, blocking of the @entity12 receptor by @entity13 (Cangrelor) resulted in strongly reduced @entity6 in @entity0 with elevated @entity2 levels compared with normocholesterolemic controls. CONCLUSIONS: These data revealed that the @entity12 receptor pathway was substantially involved in @entity6 associated with mild and severe @entity5 .

title: Contribution of the @entity12 receptor-mediated pathway to @entity6 in XXXX .

answer: @entity5


abstract: BACKGROUND: In @entity5 , platelets demonstrate increased reactivity and promote the development of @entity1 . OBJECTIVE: This study was carried out to investigate the contribution of the @entity4 receptor @entity12 -mediated pathway to @entity6 due to @entity5 . METHODS: @entity7 -deficient @entity0 and C57Bl/6 wild-type @entity0 were fed on normal chow and high-fat (Western or Paigen) diets for 8 weeks to generate differently elevated @entity2 levels. @entity12 receptor-induced functional responses via G(i) signaling were studied ex vivo when washed @entity0 platelets were activated by 2MeSADP and @entity11 agonist AYPGKF in the presence and absence of @entity9 . Platelet aggregation and secretion, a(IIb)b(3) receptor activation and the phosphorylation of @entity10 ( @entity10 ) and Akt were analyzed. RESULTS: Plasma @entity2 levels ranged from 69    10 to 1011    185 mg dL(-1) depending on diet in @entity0 with different genotypes. Agonist-dependent aggregation, dense and a-granule secretion and JON/A binding were gradually and significantly (P < 0.05) augmented at low agonist concentration in correlation with the increasing plasma @entity2 levels, even if elevated @entity8 generation was blocked. These functional responses were induced via increased levels of G(i) -mediated @entity10 and Akt phosphorylation in @entity3 @entity0 vs. normocholesterolemic animals. In addition, blocking of the @entity12 receptor by @entity13 (Cangrelor) resulted in strongly reduced @entity6 in @entity0 with elevated @entity2 levels compared with normocholesterolemic controls. CONCLUSIONS: These data revealed that the @entity12 receptor pathway was substantially involved in @entity6 associated with mild and severe @entity5 .

title: Contribution of the @entity12 receptor-mediated pathway to XXXX in @entity5 .

answer: @entity6


abstract: OBJECTIVE: To examine breastfeeding and the risk of hospitalization for lower respiratory tract disease in healthy full-term @entity0 with access to modern medical care. DATA SOURCES: MEDLINE, personal communication with researchers, the OVID databases, Dissertation Abstracts Online, and BIOSIS. STUDY SELECTION: The titles, abstracts, and text of studies from developed countries were explored for breastfeeding exposure measures and lower respiratory tract disease hospitalization rates. For summary statistics, we required 3 inclusion criteria: (1) a feeding contrast of a minimum of 2 months of exclusive breastfeeding (no formula supplementation) vs no breastfeeding and (2) study populations that excluded sick, low birth weight or premature @entity0 and (3) reflected affluent regions; 27% of studies met these criteria. DATA EXTRACTION: We abstracted data from all relevant reports. DATA SYNTHESIS: Data from all primary material (33 studies) indicated a protective association between breastfeeding and the risk of @entity1 hospitalization. Nine studies met all inclusion criteria, and 7 cohort studies were pooled. The feeding contrasts in these 7 studies were 4 or more months of exclusive breastfeeding vs no breastfeeding. The summary relative risk (95% confidence interval) was 0.28 (0.14-0.54), using a random-effects model. This effect remained stable and statistically significant after adjusting for the effects of smoking or socioeconomic status. CONCLUSION: Among generally healthy @entity0 in developed nations, more than a tripling in severe respiratory tract illnesses resulting in hospitalizations was noted for @entity0 who were not breastfed compared with those who were exclusively breastfed for 4 months.

title: Breastfeeding and the risk of hospitalization for XXXX in infancy: a meta-analysis.

answer: @entity1


abstract: UNASSIGNED: Individual joint deviations are often identified in the analysis of @entity1 ( @entity1 ) gait. However, knowledge is limited as to how these deviations affect the control of the locomotor system as a whole when striving to meet the demands of walking. The current study aimed to bridge the gap by describing the control of the locomotor system in @entity0 with @entity1 in terms of their leg @entity2 , and associated joint @entity3 during gait. Twelve @entity0 with @entity5 and 12 healthy controls walked at a self-selected pace in a gait laboratory while their kinematic and forceplate data were measured and analyzed during loading response, mid-stance, terminal stance and pre-swing. For calculating the leg @entity3 , each of the lower limbs was modeled as a non-linear spring, connecting the hip joint center and the corresponding center of pressure, with varying @entity3 that was calculated as the slope (gradient) of the axial force vs. the deformation curve. The leg @entity3 was further decomposed into skeletal and muscular components considering the alignment of the lower limb. The ankle, knee and hip of the limb were modeled as @entity4 with torsional springs whose @entity3 was calculated as the slope of the moment vs. the angle curve of the joint. Independent t-tests were performed for between-group comparisons of all the variables. The @entity1 group significantly decreased the leg @entity3 but increased the joint @entity3 during stance phase, except during terminal stance where the leg @entity3 was increased. They appeared to rely more on muscular contributions to achieve the required leg @entity3 , increasing the muscular demands in maintaining the body posture against collapse. Leg @entity3 plays a critical role in modulating the kinematics and kinetics of the locomotor system during gait in the @entity1 .

title: Leg and Joint Stiffness in @entity0 with Spastic XXXX during Level Walking.

answer: @entity1


abstract: UNASSIGNED: Individual joint deviations are often identified in the analysis of @entity1 ( @entity1 ) gait. However, knowledge is limited as to how these deviations affect the control of the locomotor system as a whole when striving to meet the demands of walking. The current study aimed to bridge the gap by describing the control of the locomotor system in @entity0 with @entity1 in terms of their leg @entity2 , and associated joint @entity3 during gait. Twelve @entity0 with @entity5 and 12 healthy controls walked at a self-selected pace in a gait laboratory while their kinematic and forceplate data were measured and analyzed during loading response, mid-stance, terminal stance and pre-swing. For calculating the leg @entity3 , each of the lower limbs was modeled as a non-linear spring, connecting the hip joint center and the corresponding center of pressure, with varying @entity3 that was calculated as the slope (gradient) of the axial force vs. the deformation curve. The leg @entity3 was further decomposed into skeletal and muscular components considering the alignment of the lower limb. The ankle, knee and hip of the limb were modeled as @entity4 with torsional springs whose @entity3 was calculated as the slope of the moment vs. the angle curve of the joint. Independent t-tests were performed for between-group comparisons of all the variables. The @entity1 group significantly decreased the leg @entity3 but increased the joint @entity3 during stance phase, except during terminal stance where the leg @entity3 was increased. They appeared to rely more on muscular contributions to achieve the required leg @entity3 , increasing the muscular demands in maintaining the body posture against collapse. Leg @entity3 plays a critical role in modulating the kinematics and kinetics of the locomotor system during gait in the @entity1 .

title: Leg and Joint Stiffness in XXXX with Spastic @entity1 during Level Walking.

answer: @entity0


abstract: BACKGROUND: Shoulder @entity1 is a common musculoskeletal problem that is often chronic or recurrent. Myofascial trigger points (MTrPs) cause @entity1 and are prevalent in @entity0 with @entity1 . However, few studies have focused on @entity3 therapy. The aim of this study was to assess the effectiveness of multimodal treatment of MTrPs in @entity0 with @entity2 . METHODS: A single-assessor, blinded, randomized, controlled trial was conducted. The intervention group received comprehensive treatment once weekly consisting of manual compression of the MTrPs, manual stretching of the muscles and intermittent cold application with stretching. @entity0 were instructed to perform muscle-stretching and relaxation exercises at home and received ergonomic recommendations and advice to assume and maintain good posture. The control group remained on the waiting list for 3 months. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire score (primary outcome), Visual Analogue Scale for @entity1 (VAS-P), Global Perceived Effect (GPE) scale and the number of muscles with MTrPs were assessed at 6 and 12 weeks in the intervention group and compared with those of a control group. RESULTS: Compared with the control group, the intervention group showed significant improvement (P < 0.05) on the DASH after 12 weeks (mean difference, 7.7; 95% confidence interval (95% CI), 1.2 to 14.2), on the VAS-P1 for current @entity1 (mean difference, 13.8; 95% CI, 2.6 to 25.0), on the VAS-P2 for @entity1 in the past 7 days (mean difference, 10.2; 95% CI, 0.7 to 19.7) and VAS-P3 most severe @entity1 in the past 7 days (mean difference, 13.8; 95% CI, 0.8 to 28.4). After 12 weeks, 55% of the @entity0 in the intervention group reported improvement (from slightly improved to completely recovered) versus 14% in the control group. The mean number of muscles with active MTrPs decreased in the intervention group compared with the control group (mean difference, 2.7; 95% CI, 1.2 to 4.2). CONCLUSIONS: The results of this study show that 12-week comprehensive treatment of MTrPs in shoulder muscles reduces the number of muscles with active MTrPs and is effective in reducing symptoms and improving shoulder function in @entity0 with @entity2 . TRIAL REGISTRATION NUMBER: ISRCTN: ISRCTN75722066.

title: Treatment of myofascial trigger points in @entity0 with XXXX : a randomized, controlled trial.

answer: @entity2


abstract: BACKGROUND: Shoulder @entity1 is a common musculoskeletal problem that is often chronic or recurrent. Myofascial trigger points (MTrPs) cause @entity1 and are prevalent in @entity0 with @entity1 . However, few studies have focused on @entity3 therapy. The aim of this study was to assess the effectiveness of multimodal treatment of MTrPs in @entity0 with @entity2 . METHODS: A single-assessor, blinded, randomized, controlled trial was conducted. The intervention group received comprehensive treatment once weekly consisting of manual compression of the MTrPs, manual stretching of the muscles and intermittent cold application with stretching. @entity0 were instructed to perform muscle-stretching and relaxation exercises at home and received ergonomic recommendations and advice to assume and maintain good posture. The control group remained on the waiting list for 3 months. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire score (primary outcome), Visual Analogue Scale for @entity1 (VAS-P), Global Perceived Effect (GPE) scale and the number of muscles with MTrPs were assessed at 6 and 12 weeks in the intervention group and compared with those of a control group. RESULTS: Compared with the control group, the intervention group showed significant improvement (P < 0.05) on the DASH after 12 weeks (mean difference, 7.7; 95% confidence interval (95% CI), 1.2 to 14.2), on the VAS-P1 for current @entity1 (mean difference, 13.8; 95% CI, 2.6 to 25.0), on the VAS-P2 for @entity1 in the past 7 days (mean difference, 10.2; 95% CI, 0.7 to 19.7) and VAS-P3 most severe @entity1 in the past 7 days (mean difference, 13.8; 95% CI, 0.8 to 28.4). After 12 weeks, 55% of the @entity0 in the intervention group reported improvement (from slightly improved to completely recovered) versus 14% in the control group. The mean number of muscles with active MTrPs decreased in the intervention group compared with the control group (mean difference, 2.7; 95% CI, 1.2 to 4.2). CONCLUSIONS: The results of this study show that 12-week comprehensive treatment of MTrPs in shoulder muscles reduces the number of muscles with active MTrPs and is effective in reducing symptoms and improving shoulder function in @entity0 with @entity2 . TRIAL REGISTRATION NUMBER: ISRCTN: ISRCTN75722066.

title: Treatment of myofascial trigger points in XXXX with @entity2 : a randomized, controlled trial.

answer: @entity0


abstract: INTRODUCTION: @entity5 of the oesophagus (BSCCE) is a relatively rare variant of oesophageal malignancy. There are no established treatment strategies for pulmonary metastases of BSCCE. PRESENTATION OF CASE: A 72-year-old @entity0 underwent oesophagectomy and subsequently received a pathological diagnosis of stage IIIA (T3N1M0) BSCCE according to Union for International @entity2 Control. One year and 5 months later, he underwent partial resection of the right lung because of @entity1 of the BSCCE. One year and 6 months after the pulmonary resection, recurrence in the right lung was observed. The @entity0 was treated with concurrent chemoradiotherapy using @entity4 and @entity6 , and the lesion completely disappeared. The @entity0 is doing well without recurrence 5 years after chemoradiotherapy. DISCUSSION: In our case, the recurrent lesion in the right lung was observed after the pulmonary resection. It is difficult to determine whether the recurrent lesion is solitary or multiple and whether it is a local or @entity1 . Therefore, surgical indication must be decided carefully. Systemic chemotherapy or radiotherapy is useful to treat BSCCE @entity1 , however, appropriate, but which agents and their regimens are appropriate is not clear. Concurrent chemotherapy using @entity4 and @entity6 and radiotherapy for pulmonary BSCCE metastases may provide curative therapy and should be considered. CONCLUSION: This report describes a case of recurrent @entity3 after pulmonary resection of BSCCE @entity1 , successfully treated by concurrent chemotherapy and radiotherapy. Further studies are required to establish the indications and efficacy of these therapeutic approaches.

title: Surgical resection and chemoradiotherapy for metachronous @entity3 of XXXX .

answer: @entity5


abstract: INTRODUCTION: @entity5 of the oesophagus (BSCCE) is a relatively rare variant of oesophageal malignancy. There are no established treatment strategies for pulmonary metastases of BSCCE. PRESENTATION OF CASE: A 72-year-old @entity0 underwent oesophagectomy and subsequently received a pathological diagnosis of stage IIIA (T3N1M0) BSCCE according to Union for International @entity2 Control. One year and 5 months later, he underwent partial resection of the right lung because of @entity1 of the BSCCE. One year and 6 months after the pulmonary resection, recurrence in the right lung was observed. The @entity0 was treated with concurrent chemoradiotherapy using @entity4 and @entity6 , and the lesion completely disappeared. The @entity0 is doing well without recurrence 5 years after chemoradiotherapy. DISCUSSION: In our case, the recurrent lesion in the right lung was observed after the pulmonary resection. It is difficult to determine whether the recurrent lesion is solitary or multiple and whether it is a local or @entity1 . Therefore, surgical indication must be decided carefully. Systemic chemotherapy or radiotherapy is useful to treat BSCCE @entity1 , however, appropriate, but which agents and their regimens are appropriate is not clear. Concurrent chemotherapy using @entity4 and @entity6 and radiotherapy for pulmonary BSCCE metastases may provide curative therapy and should be considered. CONCLUSION: This report describes a case of recurrent @entity3 after pulmonary resection of BSCCE @entity1 , successfully treated by concurrent chemotherapy and radiotherapy. Further studies are required to establish the indications and efficacy of these therapeutic approaches.

title: Surgical resection and chemoradiotherapy for metachronous XXXX of @entity5 .

answer: @entity3


abstract: BACKGROUND: Genetic testing to refine @entity1 risk is available. However, little is known about factors affecting the uptake of testing for the most common hereditary @entity3 , @entity2 . This study investigated attitudes, intentions, and uptake of genetic testing within newly identified families with @entity2 . METHODS: Cohort study conducted at the National Institutes of Health between April 15, 1996, and November 20, 1999. Data were collected through questionnaires before semistructured education sessions, individual counseling sessions, and the offer of genetic testing. RESULTS: Of the 111 eligible first-degree relatives, 51% chose to participate in education and individual counseling sessions. Participation was associated with greater numbers of first-degree relatives with @entity1 ; no association was found between participation and personal history of @entity1 . Before education and individual counseling sessions, 64% of @entity0 had heard little about genetic testing for @entity1 ; however, most (97%) stated intentions to pursue testing. Fifty-one percent identified learning about their @entity0 's risks as the most important reason to consider testing. Thirty-nine percent identified the potential effect on their health insurance as the most important reason to not undergo testing. Of the 111 eligible first-degree relatives, 51% chose to undergo genetic testing. @entity0 ' intentions to pursue genetic testing were significantly affected by concerns regarding the ability to handle the emotional aspects of testing and the psychosocial effect on family members. CONCLUSIONS: Genetic counseling and testing offers the potential to focus @entity1 screening resources in individuals truly at increased risk, thereby reducing mortality and morbidity. Fears of discrimination and concerns about psychological and psychosocial issues may present barriers to the use of current @entity1 prevention strategies, including genetic counseling and testing.

title: Genetic counseling and testing in families with XXXX .

answer: @entity2


abstract: The endogenous neuropeptide @entity2 / @entity2 (N/OFQ) modulates behavioral and gastrointestinal responses to stress. Mucosal mast cells (MMCs) are primary mediators of stress-related responses in the gastrointestinal tract. We investigated the influence of N/OFQ and of the N/OFQ peptide (NOP) receptor antagonist, @entity3 , on MMCs in the @entity0 gastric fundus. N/OFQ was infused subcutaneously for 52 h at 0.1, 1 and 10  g/kg/h and at 1  g/kg/h for 4h, 52 h, 7 days and 14 days via Alzet osmotic minipumps. Density of MMCs and connective tissue mast cells (CTMCs) was assessed histochemically and immunohistochemically. Activation and location of MMCs were assessed by transmission electron microscopy. Contacts between MMCs and nerve elements were assessed by double immunofluorescence. N/OFQ (1  g/kg/h) and @entity3 (10 and 30  g/kg/h) were infused subcutaneously in the absence and presence of acute cold-restraint stress and density of MMCs was assessed. Peripheral N/OFQ dose-dependently increased the density of MMCs, while not influencing CTMCs. The increasing effect was maintained up to 14 days following continuous infusion, while after termination of the 4-h infusion, the effect declined rapidly. The peptide promoted the activation of MMCs and their migration from the lamina propria toward the epithelial layer. The association between MMCs and nerve fibers was time-dependently down-regulated following N/OFQ infusion. The stress-induced @entity1 of MMCs was not influenced by N/OFQ and abolished by @entity3 . @entity3 alone was ineffective. The present results suggest that endogenous N/OFQ could be considered a potential component of the circuit neuropeptides-mast cells-stress.

title: Long-term peripheral infusion of @entity2 / @entity2 promotes XXXX , activation and migration of mucosal mast cells in the @entity0 gastric fundus.

answer: @entity1


abstract: The endogenous neuropeptide @entity2 / @entity2 (N/OFQ) modulates behavioral and gastrointestinal responses to stress. Mucosal mast cells (MMCs) are primary mediators of stress-related responses in the gastrointestinal tract. We investigated the influence of N/OFQ and of the N/OFQ peptide (NOP) receptor antagonist, @entity3 , on MMCs in the @entity0 gastric fundus. N/OFQ was infused subcutaneously for 52 h at 0.1, 1 and 10  g/kg/h and at 1  g/kg/h for 4h, 52 h, 7 days and 14 days via Alzet osmotic minipumps. Density of MMCs and connective tissue mast cells (CTMCs) was assessed histochemically and immunohistochemically. Activation and location of MMCs were assessed by transmission electron microscopy. Contacts between MMCs and nerve elements were assessed by double immunofluorescence. N/OFQ (1  g/kg/h) and @entity3 (10 and 30  g/kg/h) were infused subcutaneously in the absence and presence of acute cold-restraint stress and density of MMCs was assessed. Peripheral N/OFQ dose-dependently increased the density of MMCs, while not influencing CTMCs. The increasing effect was maintained up to 14 days following continuous infusion, while after termination of the 4-h infusion, the effect declined rapidly. The peptide promoted the activation of MMCs and their migration from the lamina propria toward the epithelial layer. The association between MMCs and nerve fibers was time-dependently down-regulated following N/OFQ infusion. The stress-induced @entity1 of MMCs was not influenced by N/OFQ and abolished by @entity3 . @entity3 alone was ineffective. The present results suggest that endogenous N/OFQ could be considered a potential component of the circuit neuropeptides-mast cells-stress.

title: Long-term peripheral infusion of XXXX / @entity2 promotes @entity1 , activation and migration of mucosal mast cells in the @entity0 gastric fundus.

answer: @entity2


abstract: The endogenous neuropeptide @entity2 / @entity2 (N/OFQ) modulates behavioral and gastrointestinal responses to stress. Mucosal mast cells (MMCs) are primary mediators of stress-related responses in the gastrointestinal tract. We investigated the influence of N/OFQ and of the N/OFQ peptide (NOP) receptor antagonist, @entity3 , on MMCs in the @entity0 gastric fundus. N/OFQ was infused subcutaneously for 52 h at 0.1, 1 and 10  g/kg/h and at 1  g/kg/h for 4h, 52 h, 7 days and 14 days via Alzet osmotic minipumps. Density of MMCs and connective tissue mast cells (CTMCs) was assessed histochemically and immunohistochemically. Activation and location of MMCs were assessed by transmission electron microscopy. Contacts between MMCs and nerve elements were assessed by double immunofluorescence. N/OFQ (1  g/kg/h) and @entity3 (10 and 30  g/kg/h) were infused subcutaneously in the absence and presence of acute cold-restraint stress and density of MMCs was assessed. Peripheral N/OFQ dose-dependently increased the density of MMCs, while not influencing CTMCs. The increasing effect was maintained up to 14 days following continuous infusion, while after termination of the 4-h infusion, the effect declined rapidly. The peptide promoted the activation of MMCs and their migration from the lamina propria toward the epithelial layer. The association between MMCs and nerve fibers was time-dependently down-regulated following N/OFQ infusion. The stress-induced @entity1 of MMCs was not influenced by N/OFQ and abolished by @entity3 . @entity3 alone was ineffective. The present results suggest that endogenous N/OFQ could be considered a potential component of the circuit neuropeptides-mast cells-stress.

title: Long-term peripheral infusion of @entity2 / XXXX promotes @entity1 , activation and migration of mucosal mast cells in the @entity0 gastric fundus.

answer: @entity2


abstract: The endogenous neuropeptide @entity2 / @entity2 (N/OFQ) modulates behavioral and gastrointestinal responses to stress. Mucosal mast cells (MMCs) are primary mediators of stress-related responses in the gastrointestinal tract. We investigated the influence of N/OFQ and of the N/OFQ peptide (NOP) receptor antagonist, @entity3 , on MMCs in the @entity0 gastric fundus. N/OFQ was infused subcutaneously for 52 h at 0.1, 1 and 10  g/kg/h and at 1  g/kg/h for 4h, 52 h, 7 days and 14 days via Alzet osmotic minipumps. Density of MMCs and connective tissue mast cells (CTMCs) was assessed histochemically and immunohistochemically. Activation and location of MMCs were assessed by transmission electron microscopy. Contacts between MMCs and nerve elements were assessed by double immunofluorescence. N/OFQ (1  g/kg/h) and @entity3 (10 and 30  g/kg/h) were infused subcutaneously in the absence and presence of acute cold-restraint stress and density of MMCs was assessed. Peripheral N/OFQ dose-dependently increased the density of MMCs, while not influencing CTMCs. The increasing effect was maintained up to 14 days following continuous infusion, while after termination of the 4-h infusion, the effect declined rapidly. The peptide promoted the activation of MMCs and their migration from the lamina propria toward the epithelial layer. The association between MMCs and nerve fibers was time-dependently down-regulated following N/OFQ infusion. The stress-induced @entity1 of MMCs was not influenced by N/OFQ and abolished by @entity3 . @entity3 alone was ineffective. The present results suggest that endogenous N/OFQ could be considered a potential component of the circuit neuropeptides-mast cells-stress.

title: Long-term peripheral infusion of @entity2 / @entity2 promotes @entity1 , activation and migration of mucosal mast cells in the XXXX gastric fundus.

answer: @entity0


abstract: BACKGROUND: Recent developments in computer technology have raised expectations that fully automated diagnostic instruments will become available to diagnose @entity1 without the need of @entity0 expertise. OBJECTIVES: To critically review the contemporary literature on computer diagnosis of @entity1 , evaluate the accuracy of such computer diagnosis, analyze the influence of study characteristics, and compare the accuracy of computer diagnosis of @entity1 with @entity0 diagnosis. METHODS: Quantitative meta-analysis of published reports. DATA SOURCES: Eligible studies were identified by a MEDLINE search covering the period from January 1991 to March 2002, by manual searches of the reference lists of retrieved articles, and by direct communication with experts. RESULTS: Thirty studies with substantial differences in methodological quality were deemed eligible for meta-analysis. Five of these complied with the predetermined list of "good quality" requirements, but none met all methodological quality requirements. Ten of these studies compared the performance of computer diagnosis with @entity0 diagnosis. The diagnostic accuracy achieved with computer diagnosis was statistically not different from that of @entity0 diagnosis (log odds ratios, 3.36 vs 3.51; P =.80). The diagnostic performance of the computer diagnosis was better for studies that used dermoscopic images than for studies that used clinical images (log odds ratios, 4.2 vs 3.4; P =.08). Other study characteristics did not significantly influence the accuracy of the computer diagnosis. CONCLUSIONS: The computer diagnosis of @entity1 is accurate under experimental conditions, but the practical value of automated diagnostic instruments under real-world conditions is currently unknown. We suggest minimum requirements for methodological quality in future experimental studies or, ideally, randomized controlled trials.

title: Accuracy of computer diagnosis of XXXX : a quantitative meta-analysis.

answer: @entity1


abstract: PURPOSE: To evaluate the change in reading-performance parameters after implantation of the Kamra small-aperture intracorneal inlay over a 2-year follow-up. SETTING: University Eye Clinic, Paracelsus Medical University, Salzburg, Austria. DESIGN: Cohort study. METHODS: This study comprised naturally emmetropic presbyopic @entity0 . Bilateral reading acuity, reading distance, reading speed, and the smallest log-scaled sentence were evaluated in a standardized testing procedure using the Salzburg Reading Desk. The minimum postoperative follow-up was 24 months. RESULTS: The study enrolled 32 @entity0 . The reading desk results showed a significant improvement in each parameter tested. After a mean follow-up of 24.2 months    0.8 (SD), the mean reading distance changed from the preoperative value of 48.1    5.5 cm to 38.9    6.3 cm (P < .0001), the mean reading acuity at best distance improved from 0.3    0.14 logRAD to 0.24    0.11 logRAD (P < .000001), and the mean reading speed increased from 142    13 words per minute (wpm) to 149    17 wpm (P=.029). One @entity0 @entity2 line, and 1 @entity0 had no change. The improvement was up to 6 log-scaled lines (mean improvement 2.7    1.6 lines) in the other 30 @entity0 . CONCLUSIONS: After implantation of the small-aperture intracorneal inlay, there was an improvement in all tested reading performance parameters in emmetropic presbyopic @entity0 ; the improvement was the result of an increased depth of field. These 2-year results indicate that the inlay is an effective treatment for @entity1 .

title: Reading performance after implantation of a small-aperture corneal inlay for the surgical correction of XXXX : Two-year follow-up.

answer: @entity1


abstract: OBJECTIVE: To study the histogenesis, pathologic features and differential diagnosis of prostatic primary @entity4 . METHODS: 10 cases of the primary @entity4 were detected from 262 cases of @entity2 diagnosed on needle biopsy were investigated by routine pathological, immunohistochemical and histochemical methods, and then compared with 10 cases of signet ring cell @entity1 of the stomach and colon. 3 cases were studied with electron microscopy. RESULTS: 9 cases of @entity2 were associated with concurrent high-grade conventional @entity2 , but at least 25% of the @entity0 consisted of signet ring cells. Only one case was @entity4 . Neoplastic signet ring cells may be divided into two types: the first type showed formation of intracytoplasmic lumina or vacuole, and the second type had intracytoplasmic accumulation of @entity7 . Both types of signet ring cells were negative for @entity5 staining (AB/PAS and @entity6 ). Therefore they differed from signet ring cell @entity1 of the stomach and colon. CONCLUSIONS: Primary @entity2 is a low-differentiated @entity3 of a special histologic type, which arises from the epithelial cells of the prostate acinus. They can be distinguished from metastatic @entity4 of the stomach and colon and also from vacuolate degeneration of conventional @entity1 after endocrine or radiation therapy.

title: [Pathologic diagnosis and histogenesis of primary XXXX of the prostate].

answer: @entity4


abstract: INTRODUCTION AND OBJECTIVES: Gated-SPECT simultaneously evaluates perfusion and ventricular function and could provide important prognostic information in @entity2 . Our aim was to study the value of gated-SPECT performed before revascularization in a cardioischemic population to predict the outcome of revascularization. METHODS: One hundred and ten @entity0 who had undergone percutaneous (n = 100) or surgical revascularization were included. @entity0 underwent sestamibi gated-SPECT before revascularization. After revascularization, they were followed-up for at least 12 months (mean 23.7 months, maximum 44 months). We recorded @entity1 and a combined clinical event of @entity1 , non-fatal @entity3 , and hospital re-admission for cardiac reasons. We analyzed the prognostic value of clinical, angiographic, and gated-SPECT variables. RESULTS: During follow-up, there were 14 @entity1 (6.4%/ year) and 36 cases of combined events (16.5%/year). Multivariate analysis showed that depressed gated-SPECT ejection fraction (threshold 0.30) was the only variable independently related to @entity1 (OR = 4.8; 95%CI, 1.6-14.6) and combined event (OR = 2.5; 95%CI, 1.2-4.8). Survival analysis showed that @entity0 with ejection fraction < or = 0.30% had a significantly shorter period of time free of @entity1 (33 months [28-38] versus 42 months [40-44]; p = 0.002) and combined events (28 months [23-32] versus 36 months [33-39]; p = 0.007). CONCLUSIONS: Gated-SPECT, due to the information it provides about left ventricular function, predicts the prognosis of @entity0 after coronary revascularization.

title: [Value of gated-SPECT in defining the post-revascularization prognosis of @entity0 with XXXX ].

answer: @entity2


abstract: INTRODUCTION AND OBJECTIVES: Gated-SPECT simultaneously evaluates perfusion and ventricular function and could provide important prognostic information in @entity2 . Our aim was to study the value of gated-SPECT performed before revascularization in a cardioischemic population to predict the outcome of revascularization. METHODS: One hundred and ten @entity0 who had undergone percutaneous (n = 100) or surgical revascularization were included. @entity0 underwent sestamibi gated-SPECT before revascularization. After revascularization, they were followed-up for at least 12 months (mean 23.7 months, maximum 44 months). We recorded @entity1 and a combined clinical event of @entity1 , non-fatal @entity3 , and hospital re-admission for cardiac reasons. We analyzed the prognostic value of clinical, angiographic, and gated-SPECT variables. RESULTS: During follow-up, there were 14 @entity1 (6.4%/ year) and 36 cases of combined events (16.5%/year). Multivariate analysis showed that depressed gated-SPECT ejection fraction (threshold 0.30) was the only variable independently related to @entity1 (OR = 4.8; 95%CI, 1.6-14.6) and combined event (OR = 2.5; 95%CI, 1.2-4.8). Survival analysis showed that @entity0 with ejection fraction < or = 0.30% had a significantly shorter period of time free of @entity1 (33 months [28-38] versus 42 months [40-44]; p = 0.002) and combined events (28 months [23-32] versus 36 months [33-39]; p = 0.007). CONCLUSIONS: Gated-SPECT, due to the information it provides about left ventricular function, predicts the prognosis of @entity0 after coronary revascularization.

title: [Value of gated-SPECT in defining the post-revascularization prognosis of XXXX with @entity2 ].

answer: @entity0


abstract: Cardiac sarcoplasmic reticulum (SR) sequesters @entity1 and plays a crucial role in the regulation of intracellular @entity1 . Its functional properties are central to the excitation-contraction cycle of cardiac muscle. In this study, we hypothesized that alterations in SR function occur during the development of left ventricular (LV) @entity4 . @entity6 was produced in Lewis @entity0 by the one-kidney, one-clip (1K1C) procedure. LV tissues were obtained from 1K1C @entity0 1 week (mild, N=7), 4 weeks (moderate, N=7), and 8 weeks (severe, N=7) post-surgery and from the corresponding age-matched, sham-operated controls (N=7 at each stage). In all of these @entity0 , the ratio of LV weight (g) to body weight (kg) was determined and considered as an index for @entity6 . In addition, the ratio of lung weight (g) to body weight (kg) was determined and considered as an index for @entity3 and @entity2 . In each LV specimen, SR @entity1 -uptake and tissue @entity1 -ATPase ( @entity5 ) level were determined. In 1K1C @entity0 , @entity6 increased by 21, 40, and 90% at 1, 4, and 8 weeks post-surgery, respectively, compared to the age-matched, sham-operated @entity0 , whereas @entity3 did not occur at 1 and 4 weeks but increased significantly by about 21% at 8 weeks. Further, both SR @entity1 -uptake and immunodetectable @entity5 level did not change at 1 week, increased (54%) to the same extent at 4 weeks, and decreased (42%) by approximately the same extent at 8 weeks in 1K1C @entity0 compared to the age-matched, sham-operated @entity0 . In summary, as @entity6 evolved, @entity1 -uptake and @entity5 expression did not change in the early, increased in the moderate, and then declined in the later stages of @entity4 development. The increase in @entity1 -uptake and @entity5 expression suggests, at the cellular level, a compensatory response to @entity6 , while the decline at later stages indicates the transition to @entity2 .

title: Assessment of sarcoplasmic reticulum @entity1 -uptake during the development of XXXX .

answer: @entity6


abstract: Cardiac sarcoplasmic reticulum (SR) sequesters @entity1 and plays a crucial role in the regulation of intracellular @entity1 . Its functional properties are central to the excitation-contraction cycle of cardiac muscle. In this study, we hypothesized that alterations in SR function occur during the development of left ventricular (LV) @entity4 . @entity6 was produced in Lewis @entity0 by the one-kidney, one-clip (1K1C) procedure. LV tissues were obtained from 1K1C @entity0 1 week (mild, N=7), 4 weeks (moderate, N=7), and 8 weeks (severe, N=7) post-surgery and from the corresponding age-matched, sham-operated controls (N=7 at each stage). In all of these @entity0 , the ratio of LV weight (g) to body weight (kg) was determined and considered as an index for @entity6 . In addition, the ratio of lung weight (g) to body weight (kg) was determined and considered as an index for @entity3 and @entity2 . In each LV specimen, SR @entity1 -uptake and tissue @entity1 -ATPase ( @entity5 ) level were determined. In 1K1C @entity0 , @entity6 increased by 21, 40, and 90% at 1, 4, and 8 weeks post-surgery, respectively, compared to the age-matched, sham-operated @entity0 , whereas @entity3 did not occur at 1 and 4 weeks but increased significantly by about 21% at 8 weeks. Further, both SR @entity1 -uptake and immunodetectable @entity5 level did not change at 1 week, increased (54%) to the same extent at 4 weeks, and decreased (42%) by approximately the same extent at 8 weeks in 1K1C @entity0 compared to the age-matched, sham-operated @entity0 . In summary, as @entity6 evolved, @entity1 -uptake and @entity5 expression did not change in the early, increased in the moderate, and then declined in the later stages of @entity4 development. The increase in @entity1 -uptake and @entity5 expression suggests, at the cellular level, a compensatory response to @entity6 , while the decline at later stages indicates the transition to @entity2 .

title: Assessment of sarcoplasmic reticulum XXXX -uptake during the development of @entity6 .

answer: @entity1


abstract: OBJECTIVE: To test the hypothesis that tenidap has a structure-modifying effect in @entity0 @entity2 . DESIGN:                 <AbstractText Label="STUDY" NlmCategory="METHODS">multicenter, prospective, randomized, double blind, 1 year duration. @entity0 : primary @entity1 (ACR criteria) of the medial tibiofemoral compartment, medial joint space width > or =2mm, at least 10% of one cartilage surface of the medial compartment affected by superficial fibrillation or worse at baseline arthroscopy. STUDY MEDICATION: once daily dosage of either tenidap 40 mg, tenidap 120 mg or @entity4 20mg. STUDY ENDPOINTS: bilateral extended weight-bearing X-rays and knee arthroscopy under local anaesthesia were done at entry and after 1 year. Joint space width was measured in millimeters at the narrowest point of the medial compartment. Chondropathy was scored by using reader's overall assessment (VAS score, 100mm) and Soci  t   Fran  aise d'Arthroscopie ( @entity5 ) score (0-100). RESULTS: @entity0 (665) were randomized and 494 completed the study. After 1 year, intra-group radiological changes and radiological difference between both tenidap groups and the @entity4 group did not reach statistical significance. The intra-group arthroscopic @entity3 was low, but statistically significant in the three study groups. However, there was no statistically significant difference between both tenidap groups and the @entity4 group. CONCLUSIONS: This study failed to demonstrate any difference between the treatment arms with regard to the structural progression of medial @entity2 as measured by radiography and arthroscopy. Arthroscopy did, however, appears to be more sensitive in detecting disease progression than the weight-bearing radiographs with fully extended knees. This study shows that it is possible to complete a large international trial using arthroscopy as an outcome measure of articular cartilage.

title: Arthroscopic evaluation of potential structure-modifying @entity2 . A multicenter, randomized, double-blind comparison of tenidap sodium vs XXXX .

answer: @entity4